The breast carcinomas analyzed in this clinical trial presented high-risk clinical and biological characteristics predominating size T3/T4 size, positive axilla, clinical stage III, histological grade III, non-luminal carcinoma A, negative ER and Ki-67 ≥ 20%. The gene discussed is MKI67; the disease is breast carcinoma.